BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...
Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...
Zacks.com on MSN2d
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...
Seeking Alpha on MSN3d
BioNTech to buy bispecific antibody developer Biotheus for up to $950MBioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
Zacks.com on MSN1d
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback